174 related articles for article (PubMed ID: 11264551)
1. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure.
Vesely DL; Perez-Lamboy GI; Schocken DD
J Card Fail; 2001 Mar; 7(1):55-63. PubMed ID: 11264551
[TBL] [Abstract][Full Text] [Related]
2. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.
Vesely DL; Perez-Lamboy GI; Schocken DD
Metabolism; 2000 Dec; 49(12):1592-7. PubMed ID: 11145122
[TBL] [Abstract][Full Text] [Related]
3. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?
Vesely DL
Clin Exp Pharmacol Physiol; 2006 Mar; 33(3):169-76. PubMed ID: 16487258
[TBL] [Abstract][Full Text] [Related]
4. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
Vesely DL; San Miguel GI; Hassan I; Schocken DD
Horm Metab Res; 2002 May; 34(5):245-9. PubMed ID: 12063637
[TBL] [Abstract][Full Text] [Related]
5. Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2.
Vesely DL; Perez-Lamboy GI; Schocken DD
Life Sci; 2000; 66(10):905-13. PubMed ID: 10714891
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure.
Patel H; Dietz JR; Owen A; San Miguel G; McCormick MT; Schocken DD; Vesely DL
Exp Biol Med (Maywood); 2004 Jun; 229(6):521-7. PubMed ID: 15169971
[TBL] [Abstract][Full Text] [Related]
7. Intact negative feedback of four cardiac hormones in congestive heart failure.
Vesely DL; San Miguel GI; Hassan I; Schocken DD
Metabolism; 2002 May; 51(5):582-8. PubMed ID: 11979389
[TBL] [Abstract][Full Text] [Related]
8. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man.
McMurray J; Seidelin PH; Howey JE; Balfour DJ; Struthers AD
J Hypertens; 1988 Oct; 6(10):783-6. PubMed ID: 2974052
[TBL] [Abstract][Full Text] [Related]
9. Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.
Vesely DL; Dietz JR; Parks JR; Antwi EA; Overton RM; McCormick MT; Cintron G; Schocken DD
Am Heart J; 1999 Oct; 138(4 Pt 1):625-32. PubMed ID: 10502206
[TBL] [Abstract][Full Text] [Related]
10. Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure.
Nasser A; Dietz JR; Siddique M; Patel H; Khan N; Antwi EK; San Miguel GI; McCormick MT; Schocken DD; Vesely DL
Am J Cardiol; 2001 Jul; 88(1):23-9. PubMed ID: 11423053
[TBL] [Abstract][Full Text] [Related]
11. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones.
Vesely DL; Eichelbaum EJ; Sun Y; Alli AA; Vesely BA; Luther SL; Gower WR
In Vivo; 2007; 21(3):445-51. PubMed ID: 17591353
[TBL] [Abstract][Full Text] [Related]
12. Atrial natriuretic peptides in the diagnosis and treatment of congestive heart failure.
Vesely DL
Congest Heart Fail; 1999; 5(4):171-179. PubMed ID: 12189309
[TBL] [Abstract][Full Text] [Related]
13. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and tree T4 and free T3 with reciprocal increase in TSH.
Vesely DL; San Miguel GI; Hassan I; Gower WR; Schocken DD
J Clin Endocrinol Metab; 2001 Nov; 86(11):5438-42. PubMed ID: 11701719
[TBL] [Abstract][Full Text] [Related]
14. Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion.
Ackerman BH; Overton RM; McCormick MT; Schocken DD; Vesely DL
J Pharmacol Exp Ther; 1997 Aug; 282(2):603-8. PubMed ID: 9262321
[TBL] [Abstract][Full Text] [Related]
15. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.
Chiou S; Vesely DL
Endocrinology; 1995 May; 136(5):2033-9. PubMed ID: 7720651
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic approach for cancer using four cardiovascular hormones.
Vesely DL; Clark LC; Garces AH; McAfee QW; Soto J; Gower WR
Eur J Clin Invest; 2004 Oct; 34(10):674-82. PubMed ID: 15473892
[TBL] [Abstract][Full Text] [Related]
17. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
Sun Y; Eichelbaum EJ; Skelton WP; Lenz A; Wang H; Vesely DL
Anticancer Res; 2009 Apr; 29(4):971-5. PubMed ID: 19414334
[TBL] [Abstract][Full Text] [Related]
18. Four peptide hormones decrease the number of human breast adenocarcinoma cells.
Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Solivan SM; Gower WR; Vesely DL
Eur J Clin Invest; 2005 Jan; 35(1):60-9. PubMed ID: 15638821
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression.
Vesely DL
IUBMB Life; 2002 Mar; 53(3):153-9. PubMed ID: 12102171
[TBL] [Abstract][Full Text] [Related]
20. Five cardiac hormones decrease the number of human small-cell lung cancer cells.
Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Alli AA; Solivan SM; Gower WR; Vesely DL
Eur J Clin Invest; 2005 Jun; 35(6):388-98. PubMed ID: 15948900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
